Immediate Impact
4 from Science/Nature 69 standout
Citing Papers
PI3K/Akt/mTOR Signaling Pathway as a Target for Colorectal Cancer Treatment
2024 Standout
Expanded ROS Generation and Hypoxia Reversal: Excipient‐free Self‐assembled Nanotheranostics for Enhanced Cancer Photodynamic Immunotherapy
2024 Standout
Works of Emin Avşar being referenced
Phase 2 results: Encorafenib (ENCO) and cetuximab (CETUX) with or without alpelisib (ALP) in patients with advanced BRAF-mutant colorectal cancer (BRAFm CRC).
2016
Phase II study of the HSP90 inhibitor AUY922 in patients with previously treated, advanced non-small cell lung cancer (NSCLC).
2012
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Emin Avşar | 142 | 369 | 290 | 18 | 615 | |
| Christopher Ware | 120 | 189 | 376 | 11 | 707 | |
| Meejeon Roh | 131 | 249 | 403 | 20 | 727 | |
| Eileen L. Heinrich | 91 | 410 | 320 | 15 | 734 | |
| Rajesh Patel | 53 | 174 | 298 | 18 | 594 | |
| Kevin McMahon | 313 | 184 | 318 | 15 | 721 | |
| Charlotte Shinn | 71 | 223 | 363 | 16 | 715 | |
| Weihong Cao | 75 | 277 | 383 | 27 | 719 | |
| Yun Gyu Park | 43 | 200 | 517 | 22 | 727 | |
| Tushar B. Deb | 82 | 194 | 496 | 28 | 707 | |
| Jared J. Fradette | 102 | 264 | 307 | 22 | 637 |
All Works
Loading papers...